Minerva Neurosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Minerva Neurosciences, Inc.
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
With 37 Novel Approvals in 2022, US FDA CDER’s Five-Year Hot Streak Comes To An End; Gene Therapies Carry CBER To 8 Novel Approvals
US FDA’s novel agent count fell back to average as agency kept up high rate of complete response letters and refuse to file actions; CBER’s workload shifted to regenerative medicine.
Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Waiting Game For Minerva After Roluperidone US Filing
The firm’s potential new therapy for the negative symptoms of schizophrenia is now in the hands of the US Food and Drug Administration – some have concerns over whether the supporting data will be enough.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Cyrenaic Pharmaceuticals, Inc.
- Mind-NRG SA
- Sonkei Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.